AI Article Synopsis
- Demodex blepharitis is a common eyelid disease affecting about 25 million Americans, caused by Demodex mites that can lead to mechanical damage, bacterial infection, and inflammation.
- Risk factors include older age, rosacea, and diabetes, with symptoms like redness, dryness, discomfort, and the presence of collarettes, which are indicative of the condition.
- Multiple management options exist, but none are FDA approved; however, a recent clinical trial suggests that lotilaner ophthalmic solution could effectively treat the disease by eradicating the Demodex mites and reducing symptoms.
Article Abstract
Demodex blepharitis is a common disease of the eyelid, affecting approximately 25 million Americans. This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques, current management options, and emerging treatments. Demodex mites contribute to blepharitis in several ways: direct mechanical damage, as a vector for bacteria, and by inducing hypersensitivity and inflammation. Risk factors for Demodex blepharitis include increasing age, rosacea, and diabetes. The costs, symptom burden, and psychosocial effects of Demodex blepharitis are considerable. The presence of collarettes is pathognomonic for Demodex blepharitis. Redness, dryness, discomfort, foreign body sensation, lash anomalies, and itching are also hallmarks of the disease. Although a number of oral, topical, eyelid hygiene and device-based options have been used clinically and evaluated in studies for the management of Demodex blepharitis, none have been FDA approved to treat the disease. Recent randomized controlled clinical trials suggest that lotilaner ophthalmic solution, 0.25%, is a topical treatment with the potential to eradicate Demodex mites and eliminate collarettes and eyelid redness for an extended period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351901 | PMC |
| http://dx.doi.org/10.1097/ICL.0000000000001003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demodex and the eye - A review.
Indian J Ophthalmol
January 2025
Cornea, Cataract and Refractive Surgery, Darshan Eye Clinic and Surgical Centre, Chennai, Tamil Nadu, India.
Demodexblepharitis (DB) has become one of the common differential diagnoses in patients presenting with red eyes in daily clinics. In this review article, we have incorporated a detailed discussion about the mite and the various mechanisms by which it causes different signs and symptoms, the risk factors, and diagnostic methods with current and emerging treatment modalities. Because of the chronic symptoms and rather a late diagnosis, DB considerably affects patients' quality of life.
View Article and Find Full Text PDFTopical Ivermectin-metronidazole gel therapy improves Meibomian gland Function in blepharitis caused by demodex spp.
Cont Lens Anterior Eye
December 2024
Department of Ophthalmology, Molecular Pharmacology and Physiology, FL, United States; Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Purpose: To evaluate the efficacy and safety of topical Ivermectin- Metronidazol in the management of demodex infestation and their effect in Meibomian gland dysfunction (MGD) METHODS: Fifty-four patients (108 eyes) with demodex diagnosis and Meibomian gland dysfunction received Ivermectin 0.3 %+Metronidazole 0.5 % gel in the night for 5 weeks.
View Article and Find Full Text PDFIvermectin 1% Combined With Intense Pulsed Light Treatment for Dry Eye Disease Secondary to Demodex Blepharitis.
Cornea
December 2024
Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Purpose: To examine the safety and efficacy of combined treatment with topical ivermectin 1% and intense pulsed light (IPL) for dry eye disease (DED) secondary to demodex blepharitis.
Methods: A retrospective review of medical files of patients treated at a private clinic specializing in DED between November 2022 and February 2024 was performed. Sixty-one patients aged 18 years or older with DED because of demodex blepharitis, who received the IPL and ivermectin 1% combination therapy, were included.
In vitro killing effect of berberine and niclosamide on ocular Demodex folliculorum.
Cont Lens Anterior Eye
November 2024
Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China; Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian 361005, China; Department of Ophthalmology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China. Electronic address:
Purpose: To explore the in vitro killing effect of water-soluble berberine and lipid-soluble niclosamide against ocular Demodex folliculorum.
Methods: Demodex with good vigor were collected from patients' eyelashes. These mites were randomly distributed into different groups with 20 mites in each group.
Efficacy of Terpinen-4-ol Combined With Eyelid Deep Cleaning for the Treatment of Demodex Blepharitis: A Randomized, Open-Label Trial.
Transl Vis Sci Technol
November 2024
Department of Cornea & Ocular Surface Diseases, Wuhan Aier Hankou Eye Hospital, Wuhan, China.
Purpose: We aimed to evaluate the clinical efficacy of a combined treatment regimen involving terpinen-4-ol (T4O) and eyelid deep cleaning for managing Demodex blepharitis.
Methods: In this randomized, open-label trial, 40 patients diagnosed with Demodex blepharitis at the Cornea Specialty Clinic of Hankou Aier Eye Hospital were enrolled. Participants were randomly assigned to either a T4O or a combination treatment group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!